DB05410ExperimentalSmall molecule
NCX is an NO-releasing derivative of hydrocortisone.
- Mechanism
- Curator reviewed
NCX 1022 is designed to have potent anti- inflammatory activity combined with a significantly improved safety and tolerability profile, in particular the absence of skin blanching after repeated use.It is better than hydrocortisone in terms of inhibiting benzalkonium chloride-induced leukocyte adhesion to the endothelium, without affecting the flux of rolling leukocytes or venule diameter.
- Primary indication
- Investigated for use/treatment in atopic dermatitis.Curator reviewed
- Formula / weight
- C29H35NO9 · 541.597 g/mol (avg)
- Code names
- NCX-1022
Resolves to
Compound
Structure
InChIKey
MBODWAULVMWNDB-UHFFFAOYSA-NSMILESCC12CC(O)C3C(CCC4=CC(=O)CCC34C)C1CCC2(O)C(=O)COC(=O)C1=CC=CC(CON(=O)=O)=C1What you can answer from here — as of March 06, 2025
Which companies are running trials of NCX 1022, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account